Comparative Pharmacology
Head-to-head clinical analysis: BACITRACIN ZINC NEOMYCIN SULFATE POLYMYXIN B SULFATE versus KANTREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACITRACIN ZINC NEOMYCIN SULFATE POLYMYXIN B SULFATE versus KANTREX.
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE vs KANTREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bacitracin zinc inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan precursors. Neomycin sulfate and polymyxin B sulfate are aminoglycoside and polypeptide antibiotics, respectively; neomycin binds to 30S ribosomal subunit and causes misreading of mRNA, while polymyxin B disrupts bacterial cell membrane permeability by interacting with phospholipids.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis and causing mRNA misreading.
Apply topically (ointment or cream) to affected area 1-3 times daily. For ophthalmic use, instill 1-2 drops into affected eye(s) every 3-4 hours.
15 mg/kg/day IM or IV divided every 8-12 hours (not to exceed 1.5 g/day)
None Documented
None Documented
Neomycin: 2-3 h; polymyxin B: 4.5-6 h; bacitracin: 1.5 h. Combined: effectively ~2-6 h depending on renal function; clinical context: prolonged with renal impairment.
2-3 hours (normal renal function); prolonged to 30-50 hours in anuria; clinically significant accumulation in renal impairment requires monitoring
Neomycin: ~99% renal; polymyxin B: ~60% renal, 40% fecal; bacitracin: mainly renal (over 90%). Combined: renal (predominant), with minor biliary/fecal contribution (polymyxin B).
Renal: 80-100% as unchanged drug via glomerular filtration; fecal: <1%
Category A/B
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic